Literature DB >> 6721986

Pethidine binding in whole blood: methodology and clinical significance.

C La Rosa, D J Morgan, L E Mather.   

Abstract

A three-compartment equilibrium dialysis method was developed for the simultaneous and direct determination of drug binding in whole blood and in plasma and of the blood to plasma concentration ratio (b/p). The unbound fraction of pethidine in the blood of six healthy volunteers (0.63, s.d. 0.09, n = 23 determinations) was significantly different from that in the blood of six patients (0.72, s.d. 0.08, n = 24 determinations). There was no significant difference in the b/p of six patients (0.84, s.d. 0.09, n = 24 determinations) and six volunteers (0.90, s.d. 0.14, n = 23 determinations). The observed unbound fraction of pethidine in blood (0.6 to 0.7) was considerably lower than previously reported. As this value for the unbound fraction (0.6 to 0.7) is similar to the reported estimated hepatic extraction ratio of the drug in man, it is proposed that pethidine elimination should be described as 'capacity limited, binding sensitive' rather than 'flow-limited'.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721986      PMCID: PMC1463408          DOI: 10.1111/j.1365-2125.1984.tb02364.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Binding of salicylate and sulfathiazole by whole blood constituents.

Authors:  C A Cruze; M C Meyer
Journal:  J Pharm Sci       Date:  1976-01       Impact factor: 3.534

2.  Binding of chlorpromazine and imipramine to red cells, albumin, lipoproteins and other blood components.

Authors:  M H Bickel
Journal:  J Pharm Pharmacol       Date:  1975-10       Impact factor: 3.765

3.  Pentazocine binding to blood cells and plasma proteins.

Authors:  M Ehrnebo; S Agurell; L O Boréus; E Gordon; U Lönroth
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

4.  Effect of protein binding on the distribution of 5,5-diphenylhydantoin between plasma and red cells.

Authors:  P Borondy; W A Dill; T Chang; R A Buchanan; A J Glazko
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

5.  Erythrocyte uptake and plasma binding of diphenylhydantoin.

Authors:  D Kurata; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1974-08       Impact factor: 6.875

6.  Influence of route of administration on drug availability.

Authors:  M Rowland
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

7.  Novel method for studying protein binding.

Authors:  M C Meyer; D E Guttman
Journal:  J Pharm Sci       Date:  1968-09       Impact factor: 3.534

8.  The binding of paracetamol to plasma proteins of man and pig.

Authors:  B G Gazzard; A W Ford-Hutchinson; M J Smith; R Williams
Journal:  J Pharm Pharmacol       Date:  1973-12       Impact factor: 3.765

9.  Bilirubin binding by human erythrocytes.

Authors:  D Bratlid
Journal:  Scand J Clin Lab Invest       Date:  1972-02       Impact factor: 1.713

10.  Pethidine binding in plasma: effects of methodological variables.

Authors:  C La Rosa; L E Mather; D J Morgan
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

View more
  1 in total

1.  Analysis of pethidine disposition in the pregnant rat by means of a physiological flow model.

Authors:  J L Gabrielsson; P Johansson; U Bondesson; M Karlsson; L K Paalzow
Journal:  J Pharmacokinet Biopharm       Date:  1986-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.